| __timestamp | Intra-Cellular Therapies, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 20140000 |
| Thursday, January 1, 2015 | 18187286 | 37173000 |
| Friday, January 1, 2016 | 24758063 | 48616000 |
| Sunday, January 1, 2017 | 23666957 | 108488000 |
| Monday, January 1, 2018 | 30099855 | 244622000 |
| Tuesday, January 1, 2019 | 64947625 | 287000000 |
| Wednesday, January 1, 2020 | 186363444 | 354000000 |
| Friday, January 1, 2021 | 272611040 | 186000000 |
| Saturday, January 1, 2022 | 358782000 | 151000000 |
| Sunday, January 1, 2023 | 409864000 | 232600000 |
| Monday, January 1, 2024 | 267474000 |
Infusing magic into the data realm
In the competitive world of biopharmaceuticals, managing operational costs is crucial. Over the past decade, Intra-Cellular Therapies, Inc. and Ionis Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase of nearly 3,900% in SG&A expenses, peaking at $410 million in 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Ionis Pharmaceuticals experienced a more modest growth of around 1,100%, with expenses reaching $232 million in 2023. Notably, Ionis's expenses peaked in 2020, indicating a strategic shift or cost optimization in subsequent years. These trends highlight the differing strategic priorities and operational efficiencies of these two industry leaders, offering valuable insights for investors and stakeholders.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited